European Archives - Page 835 of 1024 - European Medical Journal

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

Krakow, Poland / Berlin, Germany, March 28, 2017 – Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today…

Focussed Ultrasound for Tumour Destruction

FOCUSSED ultrasound has been suggested as a future therapy for the gentler treatment of tumours of the liver. Already used readily as a diagnostic method…

Harnessing the Liver’s Fat-Burning Power

LIVER cells have been found to have their own ability to burn accumulated fat, according to Swedish researchers. A new clinical trial has been planned…

Pembrolizumab Improves Survival as a Second-Line Treatment for Urothelial Cancer

PEMBROLIZUMAB, a highly selective, humanised monoclonal antibody targeting programmed cell death 1 (PD-1), has a superior safety profile and improved…

Promising Results from Phase II Trial of Renal Cancer Drug

RESULTS published from a Phase II clinical trial have shown the potential of the investigational drug savolitinib in the treatment of c-MET-driven…

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

Tel-Aviv, Israel, March 21, 2017 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty…

WIRED Health 2017: Innovation on a Global Scale

One of the most exciting events for medical innovation in the UK, WIRED Health took place this year on 9th March with a packed agenda bursting with…

The First Successful Robot-Assisted Retinal Vein Cannulation

A REVOLUTIONARY treatment has been developed for the surgical dispersal of retinal vein occlusion clots. The procedure would not have been possible…

Scientists Develop Bioprinting Technology Capable of Synthesising Human Skin

HUMAN skin has been successfully synthesised using a three-dimensional (3D) bioprinter. Researchers at the Universidad Carlos III de Madrid, Madrid…

Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

Kraków, Poland, March 17, 2017 – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for patients…